Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2825-2834

  Matzinger, O ^a,b   Duclos, F ^b   Bergh, A van den ^c   Carrie, C ^d   Villa S ^e   Kitsios, P ^f   Poortmans, P ^g   Sundar, S ^h   van der Steen Banasik, E M ⁱ   Gulyban, A ^a   Collette, L ^a   Bolla, M ^j  

^a EORTC Headquarters ^*  (Belgium)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d CENTRE LÉON BÉRARD   (France)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^f Bank of Cyprus Oncology Center   (Cyprus)

^g DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^h NOTTINGHAM CITY HOSPITAL   (United Kingdom)

ⁱ Arnhems Radiotherapeutisch Instituut   (Netherlands)

^j GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Acute toxicity; Prostate cancer; Quality assurance; Radiotherapy; Randomised trial

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DYSURIA; FATIGUE; GASTROINTESTINAL DISEASE; HEMATURIA; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DERMATITIS; RADIATION DOSE; RECTUM HEMORRHAGE; STATISTICAL SIGNIFICANCE; THREE DIMENSIONAL IMAGING; URINARY URGENCY; URINE RETENTION; UROGENITAL TRACT DISEASE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIATION INJURIES; RADIOTHERAPY; UROLOGIC DISEASES;

EID: 70350102549     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.009     Document Type: Article

References (22)

1. Ataman F., Poortmans P., Davis J.B., et al. High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991. Eur J Cancer 40 (2004) 2411-2416
2. Matzinger O., Poortmans P., Giraud J.Y., et al. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review. Radiother Oncol 90 (2008) 285-290
3. ICRU. ICRU Report 50. Prescibing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements, ICRU, 1993.
4. Trotti A., Byhardt R., Stetz J., et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 13-47
5. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
6. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
7. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
8. Dearnaley D.P., Hall E., Lawrence D., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92 (2005) 488-498
9. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., and Lebesque J.V. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73 (2009) 685-691
10. Ghadjar P., Vock J., Vetterli D., et al. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking. Radiat Oncol 3 (2008) 35
11. Tao Y., Lefkopoulos D., Ibrahima D., et al. Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer. Acta Oncol 47 (2008) 442-450
12. Mangar S.A., Huddart R.A., Parker C.C., Dearnaley D.P., Khoo V.S., and Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 41 (2005) 908-921
13. Strigari L., Arcangeli G., Arcangeli S., and Benassi M. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. Int J Radiat Oncol Biol Phys (2008)
14. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1124-1129
15. Li X.A., Wang J.Z., Jursinic P.A., Lawton C.A., and Wang D. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1251-1257
16. van der Laan H.P., van den Bergh A., Schilstra C., Vlasman R., Meertens H., and Langendijk J.A. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 1138-1145
17. Valdagni R., Rancati T., Fiorino C., et al. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. Int J Radiat Oncol Biol Phys 71 (2008) 1065-1073
18. Yoshimura R., Iwata M., Shibuya H., Sakai Y., and Kihara K. Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer. Radiat Med 24 (2006) 553-559
19. Peeters S.T., Heemsbergen W.D., van Putten W.L., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
20. Beckendorf V., Guerif S., Le Prise E., Cosset J.M., Lefloch O., Chauvet B., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 60 4 (2004) 1056-1065
21. Dearnaley D.P., Sydes M.R., Langley R.E., et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 83 1 (2007) 31-41
22. Heemsbergen W.D., Peeters S.T., Koper P.C., Hoogeman M.S., and Lebesque J.V. Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. Int J Radiat Oncol Biol Phys 66 (2006) 3-10